Skip to main
CRIS
CRIS logo

Curis (CRIS) Stock Forecast & Price Target

Curis (CRIS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Curis Inc.'s pharmaceutical pipeline holds significant promise due to the innovative mechanism of action (MoA) of its drugs, particularly their ability to target critical mutations in leukemogenesis like IRAK4 and FLT3, which play essential roles in various cancers. The company’s robust preclinical data demonstrates a synergistic effect from dual pathway blockade, suggesting that combinations of its therapies could offer enhanced therapeutic efficacy over single-agent treatments. This combination strategy could position Curis favorably within the competitive biotechnology landscape, enhancing its potential for success in treating complex malignancies.

Bears say

Curis Inc exhibits a negative outlook due to depressed forward multiples attributed to prevailing market volatility, which undermines investor confidence. The company faces heightened cash burn risks, particularly as it accelerates pre-commercial activities without guaranteed revenue offsets from partnerships or collaborations. Additionally, there is a significant concern regarding commercial risks related to partnered assets, as potential changes in standard of care or the introduction of competitive therapies could adversely affect market demand and share.

Curis (CRIS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Curis (CRIS) Forecast

Analysts have given Curis (CRIS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Curis (CRIS) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Curis (CRIS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.